Down syndrome preleukemia and leukemia

Area of Science:

• Pediatric Oncology
• Hematology
• Genetics

Background:

• Children with Down syndrome (DS) present distinct biological and cytogenetic factors influencing leukemia treatment and prognosis.
• Myeloid leukemia of Down syndrome (ML-DS) is often preceded by transient abnormal hematopoiesis (TAM) and is associated with favorable event-free survival (EFS) rates.

Purpose of the Study:

• To highlight the unique characteristics of acute leukemias in children with Down syndrome.
• To emphasize the need for specialized therapeutic strategies and supportive care for acute lymphoblastic leukemia (ALL) in DS patients.
• To underscore the importance of clinical trial enrollment for improving leukemia-free survival in this population.

Main Methods:

• Review of existing literature on pediatric leukemia in Down syndrome.
• Analysis of treatment outcomes and survival data for ML-DS and ALL in DS.
• Identification of key factors affecting EFS and overall survival.

Main Results:

• ML-DS demonstrates high event-free survival, frequently following a preleukemic phase (TAM).
• Acute lymphoblastic leukemia (ALL) in DS patients exhibits poorer EFS and overall survival compared to non-DS ALL.
• Enrollment in therapeutic trials, including relapse protocols, is crucial for improving outcomes.

Conclusions:

• Children with DS require tailored approaches for managing acute leukemias due to their unique disease biology.
• Further research and clinical trials are essential to enhance leukemia-free survival and supportive care for ALL in DS.
• Investigating novel therapeutic agents is critical for improving outcomes in pediatric leukemia associated with Down syndrome.